CDK4 and triple-negative breast carcinoma: Therapeutic algorithms have recently evolved, including adding neoadjuvant carboplatin and immunotherapy for triple-negative breast cancer, which is common among younger women.45 Similarly, the impact of novel targeted agents, such as poly-ADP ribose polymerase inhibitors, pertuzumab, trastuzumab emtansine, or cyclin-dependent kinase 4 or 6 inhibitors, in the adjuvant setting could not be explored.